Reply
- PMID: 32961035
- DOI: 10.1002/acr.24454
Reply
Comment on
-
Ustekinumab for the Treatment of Giant Cell Arteritis.Arthritis Care Res (Hoboken). 2021 Jun;73(6):893-897. doi: 10.1002/acr.24200. Arthritis Care Res (Hoboken). 2021. PMID: 32248659 Clinical Trial.
-
Ustekinumab in Giant Cell Arteritis: Comment on the Article by Matza et al.Arthritis Care Res (Hoboken). 2021 Jul;73(7):1056-1057. doi: 10.1002/acr.24457. Epub 2021 Jun 4. Arthritis Care Res (Hoboken). 2021. PMID: 32961039 No abstract available.
References
-
- Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18.
-
- Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 2017;69:837-45.
-
- Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317-28.
-
- Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1921-7.
-
- Stelara [package insert]. Horsham PA: Janssen Pharmaceutical Companies; 2016.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
